Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew David Hellmann, Naiyer A. Rizvi, Jonathan Wade Goldman et al. · The Lancet Oncology · 2016

Cited by 963 works. doi:10.1016/s1470-2045(16)30624-6

Authors

References